AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03071718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Subjects in the Med-D group will be assigned a personalized diet prepared on the basis of own eating habits as established by 7-d food diary recalls. Energy values of habitual diets will be kept unchanged during Med-D intervention. Briefly, Med-D will be prepared so as to achieve a weekly consumption of:~* 7 portions of milk or yogurt plus whole grain cereals,~* 7 portions of nuts (30g)~* At least 3 portion of absolute legumes~* 14 portions of vegetables~* 21 portions of fruit~* 4 portions of whole grain pasta~* 3 portions of whole grain pasta with vegetables or legumes~* 7 portions of whole grain bread~* 3 portions of fish~* Extravirgin olive oil as unique source of discretional fats All subjects will be requested not to change physical activity levels during the 8 week intervention period.
Study NCT03071718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Diet
Description: Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
Study NCT04468477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6 Lead ECG
Description: Patients will be assessed with the Kardiamobile device.
Study NCT00689936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
Description: lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles
Study NCT00689936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan, Prednisone and Thalidomide
Description: Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
Study NCT02749825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelstar
Description: As labeled
Study NCT01979107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive action by the general practitioner
Description: Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.~At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results.
Study NCT00826748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
Study NCT02749825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron
Description: As labeled
Study NCT02749825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: As labeled
Study NCT02819817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aloe Vera Gel
Description: The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
Study NCT02819817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound gel
Description: The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
Study NCT03026803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT03026803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT01567410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: e-learning
Description: Braden scale and pressure ulcer classification
Study NCT04173793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT04173793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies
Study NCT04173793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins and/or Ezetimibe
Description: Lipid-lowering therapies
Study NCT01567410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional classroom training
Description: Braden scale and pressure ulcer classification
Study NCT03947554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HRG80 Panax ginseng
Description: Panax ginseng containing 63.4 mg ginsenosides
Study NCT03947554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Panax ginseng
Description: Panax ginseng containing 19.6 mg ginsenosides
Study NCT03947554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 800 mg excipient
Study NCT02708303 — intervention group
Intervention type: OTHER
Intervention: Mayo Clinic Foregut Surgery Report Card Questionnaire
Description: Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.~Data collected from the questionnaire will be entered into a database that will be maintained for future research.
Study NCT02553668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen (FiO2 1,0)
Description: Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
Study NCT02553668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facemask
Study NCT03911843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 supplementation
Description: Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
Study NCT03911843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Cholecalciferol 1000 IU/die
Study NCT03911843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplementation
Description: Cholecalciferol 1000 IU/die
Study NCT02975583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorapaxar
Description: 2.08 mg oral tablet daily
Study NCT02975583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo oral tablet daily
Study NCT02372214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training
Description: Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
Study NCT00280670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Cognitive behavioral therapy for children with autism and anxiety.
Study NCT02311218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938 and PTA 5289
Description: Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
Study NCT02311218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
Study NCT02895737 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra
Study NCT02895737 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems
Study NCT02895737 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI: CoreValve® Evolut R™, CoreValve Medtronic
Study NCT03473457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART therapy in Acute myeloid leukemia(AML)
Description: one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
Study NCT00534261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: IM injection
Study NCT03313908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: detection of the tumor lesion
Description: non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
Study NCT00604214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Description: 24 microgram/kilogram/hour, intravenous, 96 hours (hr)
Study NCT00604214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride, intravenous, 96 hours
Study NCT02895737 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems
Study NCT02063529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + Cetuximab
Description: Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study NCT02063529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOXIRI
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study NCT01015001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS x sham (placebo) rTMS
Description: Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations.
Study NCT02341079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injection
Description: Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
Study NCT01015001 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Active rTMS x sham (placebo) rTMS
Description: Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations.
Study NCT01015001 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Description: same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
Study NCT01015001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (1Hz) rTMS applied over the left temporoparietal cortex
Description: 20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
Study NCT00817479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 MG OF DEXAMETHASONE OR PLACEBO
Study NCT00817479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo saline
Study NCT02095496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellivent-ASV
Description: 12 hours of mechanical ventilation with intellivent-ASV
Study NCT02095496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ventilation
Description: 12 hours of mechanical ventilation with pressure support ventilation
Study NCT02600754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IT-PST
Description: 5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
Study NCT02600754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IT-SCM
Description: 5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
Study NCT02341079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling femoral nerve block
Description: Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
Study NCT02814019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone 150 mg film-coated tablets
Study NCT02814019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02597114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181
Description: intravenous infusion over 3-4 hours
Study NCT01809652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Implant Support Capability
Description: Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
Study NCT03697746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: paracetamol 1000 mg vial
Study NCT03478241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: single file rotary motion
Description: after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
Study NCT03478241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: multiple file rotary motion
Description: after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
Study NCT03478241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 3: single file reciprocal motion
Description: after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
Study NCT03697746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: dexketoprofen trometamol 50 mg bulb
Study NCT03697746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: ıbuprofen 400 mg vial
Study NCT01379612 — intervention group
Intervention type: OTHER
Intervention: Ultrasonic Elastography
Description: Non-invasive
Study NCT04350502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest tube drainage
Description: Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day).
Study NCT04350502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: antibiotic concentration in pleural fluid
Description: Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
Study NCT00249379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) \< 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
Study NCT04350502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid
Description: Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
Study NCT00891397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
Study NCT00891397 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill daily until discharge
Study NCT02178956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: BBI608 480 mg orally two times daily (960 mg total daily dose)
Study NCT02178956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
Study NCT02178956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
Study NCT02178956 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally two times daily
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regular Human Insulin
Description: Continuous intravenous insulin given to ICU patients with a BG > 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Study NCT02443402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Description: Continuous intravenous insulin given to ICU patients with a BG > 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Study NCT02820350 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SCD-F40
Description: CRRT with SCD
Study NCT03569059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Robotic/VR Therapy (EVR)
Description: Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.